Vaccination Clinical Trial
Official title:
A Randomized, Parallel Controlled Clinical Trial of the Safety and Immunogenicity of Hepatitis A (Live) Vaccine, Freeze-dried in Children Aged 18-24 Months Old
Subjects will be recruited and divided into 3 groups: 1. Hepatitis A(Live)Vaccine,Freeze-dried produced by Changchun Institute of Biological Products Co., Ltd 2. Hepatitis A(Live)Vaccine,Freeze-dried produced by Zhejiang Pukang Biotechnology Co., Ltd., and 3. Hepatitis A(Live)Vaccine,Freeze-dried produced by Institute of Medical Biology, Chinese Academy of Medical Sciences. After immunization, the immunogenicity and safety of three different manufacturers will be compared and the data will be analyzed.
To evaluate the safety and immunogenicity of Hepatitis A (Live) Vaccine, Freeze-dried produced by Changchhun Institute of Biological Products Co., Ltd, we design this randomized, parallel controlled study. 450 subjects are divided into 3 groups, including 1 experimental group and 2 control groups (Research Group 1, 2, and 3), each group assigned 150 subjects respectively. All subjects are aged 18-24 months old. 150 subjects from Research Group 1 will be administrated with one dose of Hepatitis A (Live) Vaccine, Freeze-dried produced by Changchhun Institute of Biological Products Co., Ltd. Blood samples are collected before vaccination and one month (30 days) later. 150 subjects from Research Group 2 will be administrated with one dose of Hepatitis A(Live)Vaccine,Freeze-dried produced by Zhejiang Pukang Biotechnology Co., Ltd. Blood samples are collected before vaccination and one month (30 days) later. 150 subjects from Research Group 3 will be administrated with one dose of Hepatitis A (Live) Vaccine, Freeze-dried produced by Institute of Medical Biology, Chinese Academy of Medical Sciences. Blood samples are collected before vaccination and one month (30 days) later. To evaluate the immunogenicity, we will detect and compare the seroconversion rates, and antibody geometric mean concentrations. The safety of all groups will be monitored as well. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05009251 -
Using Explainable AI Risk Predictions to Nudge Influenza Vaccine Uptake
|
N/A | |
Completed |
NCT03284515 -
Vaccination In Pregnancy Gene Signature: VIP Signature Study
|
||
Completed |
NCT05012163 -
Lottery Incentive Nudges to Increase Influenza Vaccinations
|
N/A | |
Recruiting |
NCT05996549 -
Cost-effectiveness of the Influenza Vaccination
|
Phase 4 | |
Completed |
NCT04323137 -
Encouraging Flu Vaccination Among High-Risk Patients Identified by ML
|
N/A | |
Completed |
NCT01224301 -
School Influenza Vaccine vs Standard of Care With Nested Trial of 2 Parent Notification Intensities
|
N/A | |
Completed |
NCT00169858 -
Long Term Immunogenicity Study of Engerix-B Vaccine in 10 Year Old Children and the Effect of Booster Injections
|
Phase 4 | |
Completed |
NCT05509283 -
Nudging Flu Vaccination in Patients at Moderately High Risk for Flu and Flu-related Complications
|
N/A | |
Completed |
NCT02907580 -
Influenza Vaccine Attitudes, Intent, and Receipt: Pediatric
|
N/A | |
Recruiting |
NCT06160999 -
Improving Uptake of Pediatric Vaccines Through Religious Conferences and Vaccines-in-a-van in Aceh, Indonesia
|
N/A | |
Recruiting |
NCT03875703 -
Post-Vaccination Biological Collection
|
||
Completed |
NCT03287830 -
Flu2Text: Text Message Reminders for 2nd Dose of Influenza Vaccine
|
N/A | |
Completed |
NCT02907645 -
Influenza Vaccine Randomized Educational Trial: Adult
|
N/A | |
Completed |
NCT03220555 -
Efficacy of the Buzzy® Device on the Prevention of Health Care Induced Pediatric Pain in a Vaccination Center
|
N/A | |
Withdrawn |
NCT05023512 -
Understanding Public Attitudes Towards the COVID-19 Vaccination
|
N/A | |
Recruiting |
NCT02937428 -
To Look or Not to Look at the Needle During Vaccination
|
Phase 3 | |
Completed |
NCT00813319 -
Girls OnGuard: HPV Vaccination Uptake Among African American Adolescent Females
|
Phase 3 | |
Completed |
NCT03104790 -
Assessment of Viral Shedding in Children Previously in Receipt of Multiple Doses of Live Attenuated Influenza Vaccine (LAIV) Compared to Influenza Vaccine-naïve Controls
|
Phase 4 | |
Completed |
NCT04780867 -
Psychological and Lifestyle Factors on Health Outcomes
|
N/A | |
Completed |
NCT03239795 -
Promoting Influenza Vaccination In General Practice Waiting Rooms
|
N/A |